Published in Br J Cancer on March 20, 2007
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol (2011) 5.39
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer (2007) 3.61
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch (2008) 2.78
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol (2009) 2.48
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn (2010) 2.44
Colorectal cancer molecular biology moves into clinical practice. Gut (2010) 2.32
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol (2010) 1.93
Personalized medicine in oncology: the future is now. Nat Rev Drug Discov (2010) 1.91
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene (2010) 1.88
Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol (2010) 1.87
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med (2010) 1.68
Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer (2009) 1.68
A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers. J Mol Diagn (2011) 1.59
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer (2008) 1.55
Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer (2010) 1.50
HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res (2010) 1.50
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol (2010) 1.36
A flexible approach for highly multiplexed candidate gene targeted resequencing. PLoS One (2011) 1.35
Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol (2009) 1.32
Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol (2011) 1.31
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther (2011) 1.31
Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2009) 1.27
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One (2011) 1.27
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist (2010) 1.26
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol (2009) 1.24
ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer. J Oncol Pract (2009) 1.24
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer (2011) 1.24
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer (2009) 1.22
FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations. Nucleic Acids Res (2007) 1.21
EGFR Signaling in Colorectal Carcinoma. Patholog Res Int (2011) 1.20
New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.17
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res (2011) 1.17
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer (2009) 1.16
KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer (2012) 1.16
Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) (2013) 1.15
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer (2012) 1.13
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer (2008) 1.13
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol (2010) 1.12
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer (2010) 1.11
Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist (2011) 1.11
KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol (2012) 1.11
Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol (2009) 1.09
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist (2011) 1.09
Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res (2008) 1.07
The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. Dtsch Arztebl Int (2009) 1.07
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst (2011) 1.06
KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol (2010) 1.05
Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol (2009) 1.05
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol (2011) 1.04
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer (2011) 1.04
EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics (2009) 1.03
Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol (2013) 1.01
Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One (2013) 1.00
SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. J Mol Diagn (2011) 1.00
The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist (2010) 1.00
KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn (2008) 0.98
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist (2011) 0.97
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics (2009) 0.95
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw (2011) 0.95
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol (2012) 0.94
Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum Samples. Clin Med Insights Pathol (2012) 0.94
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. BMC Cancer (2013) 0.93
A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer (2009) 0.93
Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new? World J Gastroenterol (2007) 0.93
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer (2010) 0.93
Optical imaging predicts tumor response to anti-EGFR therapy. Cancer Biol Ther (2010) 0.93
Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis (2011) 0.92
Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist (2010) 0.92
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer (2011) 0.92
1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy. PLoS One (2010) 0.92
Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol (2009) 0.91
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) (2014) 0.91
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. J Transl Med (2012) 0.91
Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis. Virchows Arch (2009) 0.90
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clin Cancer Res (2011) 0.90
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. Br J Cancer (2014) 0.90
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer (2009) 0.90
Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis (2011) 0.89
Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Med (2012) 0.89
ERBBs in the gastrointestinal tract: recent progress and new perspectives. Exp Cell Res (2008) 0.89
Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. World J Gastroenterol (2014) 0.89
Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. J Am Coll Surg (2011) 0.87
Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer (2014) 0.87
Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J Gastroenterol (2016) 0.87
Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. J Oncol (2009) 0.87
Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. Chemother Res Pract (2012) 0.87
Impact of KRAS Mutations on Management of Colorectal Carcinoma. Patholog Res Int (2011) 0.87
BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner. PLoS One (2012) 0.87
Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations. Int J Colorectal Dis (2010) 0.86
Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch Med Sci (2014) 0.86
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Systemic therapy for colorectal cancer. N Engl J Med (2005) 8.94
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
LigAmp for sensitive detection of single-nucleotide differences. Nat Methods (2004) 2.70
Management of advanced colorectal cancer: state of the art. Br J Cancer (2006) 1.62
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann Oncol (2003) 1.26
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg (1999) 17.03
Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg (1999) 7.29
CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med (1999) 6.06
The logistic EuroSCORE. Eur Heart J (2003) 4.94
Risk factors for anastomotic leakage after resection of rectal cancer. Br J Surg (1998) 3.45
Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet (1999) 3.14
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet (2004) 2.75
A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A (1995) 2.70
Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology (2005) 2.69
Recent emergence of new variants of Yersinia pestis in Madagascar. J Clin Microbiol (1997) 2.53
Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke (2013) 2.44
Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet (1993) 2.40
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med (2001) 2.30
Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A (1994) 2.21
Human plasma inter-alpha-trypsin inhibitor is encoded by four genes on three chromosomes. Eur J Biochem (1989) 2.12
Results of artificial sphincter in severe anal incontinence. Report of 14 consecutive implantations. Dis Colon Rectum (1996) 2.09
Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. Cancer Res (2000) 2.06
A nationwide survey of migraine in France: prevalence and clinical features in adults. GRIM. Cephalalgia (1992) 2.05
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 2.04
Results of sphincteroplasty in 86 patients with anal incontinence. Dis Colon Rectum (2000) 2.03
[Damage control laparotomy for haemorragic abdominal trauma. A retrospective multicentric study about 109 cases]. Ann Chir (2003) 1.97
High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry (2012) 1.84
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet (2005) 1.78
An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology (2012) 1.75
Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet (2001) 1.70
STARR with Contour Transtar: prospective multicentre European study. Colorectal Dis (2008) 1.69
International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang (2011) 1.69
Detection of genomic imbalances by array based comparative genomic hybridisation in fetuses with multiple malformations. J Med Genet (2005) 1.65
Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology (2007) 1.64
Close phenotypic and functional similarities between human and murine alphabeta T cells expressing invariant TCR alpha-chains. J Immunol (1997) 1.63
Treatment of hemorrhoids with circular stapler, a new alternative to conventional methods: a prospective study of 140 patients. J Am Coll Surg (2001) 1.60
Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J Med Genet (2005) 1.60
Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol (2006) 1.59
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta (2004) 1.57
Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int (1993) 1.56
PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta-analysis. Int J Cardiol (2013) 1.56
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol (2006) 1.55
Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet (1995) 1.55
Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J Virol (1998) 1.53
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet (2008) 1.53
[Individual and collective facilitators of and barriers to the use of clinical practice guidelines by physicians: a literature review]. Rev Epidemiol Sante Publique (2003) 1.52
The Paquid epidemiological program on brain ageing. Neuroepidemiology (1992) 1.51
Plasmodium falciparum induces apoptosis in human mononuclear cells. Infect Immun (1996) 1.50
Symmetric inertial confinement fusion implosions at ultra-high laser energies. Science (2010) 1.48
A rapid PCR fidelity assay. Nucleic Acids Res (1994) 1.47
Pneumothoraces and chest tube placement after CT-guided transthoracic lung biopsy using a coaxial technique: incidence and risk factors. AJR Am J Roentgenol (1999) 1.46
Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol (1997) 1.45
Postoperative management of stage II/III colon cancer: a decision analysis. Gastroenterology (1999) 1.45
Predicting outcome after acute basilar artery occlusion based on admission characteristics. Neurology (2012) 1.45
Sst I RFLP in the human inter-alpha-trypsin inhibitor heavy chain gene ITIH1. Nucleic Acids Res (1988) 1.44
Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol (1998) 1.43
[The Paquid research program on the epidemiology of dementia. Methods and initial results]. Rev Neurol (Paris) (1991) 1.43
Pancreatic metastasis of renal cell carcinoma: presentation, treatment and survival. J Urol (2001) 1.42
Comparison of CT perfusion and angiography and MRI in selecting stroke patients for acute treatment. Neurology (2007) 1.42
Misdiagnosed malignancy in transplanted organs. Transpl Int (1993) 1.40
Abdominal radiotherapy is a cause for chronic pancreatitis. Gastroenterology (1993) 1.40
The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg (1987) 1.40
[What are the real indications for hepatectomies in metastases of colorectal origin?]. Gastroenterol Clin Biol (1998) 1.39
[Is sentinel lymph node mapping relevant for colon cancer?: a feasibility study]. Ann Chir (2003) 1.39
Propofol versus thiopental by target controlled infusion in patients undergoing craniotomy. Minerva Anestesiol (2013) 1.39
Control of pelvic symptoms in patients with rectal cancer and synchronous metastases. Gastroenterol Clin Biol (2009) 1.38
Botulinum A toxin as a treatment for overactive rectum with associated faecal incontinence. Colorectal Dis (2012) 1.38
Agreement between patients' and proxies' reports of quality of life in Alzheimer's disease. Qual Life Res (2001) 1.35
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol (1998) 1.34
Outcomes and costs of coronary artery bypass grafting: comparison between octogenarians and septuagenarians at a tertiary care centre. CMAJ (2001) 1.33
Patient safety in developing countries: retrospective estimation of scale and nature of harm to patients in hospital. BMJ (2012) 1.33
Does EuroSCORE work in individual European countries? Eur J Cardiothorac Surg (2000) 1.32
Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer (2008) 1.32
Surgical treatment of postoperative incisional hernias by intraperitoneal insertion of dacron mesh and an aponeurotic graft: a report on 250 cases. Arch Surg (1999) 1.30
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer (2001) 1.30
Derivation and validation of a mortality-risk index from a cohort of frail elderly patients hospitalised in medical wards via emergencies: the SAFES study. Eur J Epidemiol (2008) 1.28
Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet (1997) 1.27
Laparoscopic cholecystectomy in acute cholecystitis. A prospective comparative study in patients with acute vs. chronic cholecystitis. Surg Endosc (2000) 1.27
The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene (1996) 1.27
Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum Mol Genet (1998) 1.27
Resection of liver metastases from colorectal cancer: the real impact of the surgical margin. Eur J Surg Oncol (1998) 1.26
Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet (1996) 1.26
Etiology of first-ever ischaemic stroke in European young adults: the 15 cities young stroke study. Eur J Neurol (2013) 1.25
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer (1998) 1.23
Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann Surg (2000) 1.22
[Experiences in the long term treatment of collagen diseases with azathioprine (imuran)]. Med Klin (1968) 1.22
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer (2009) 1.22